Welcure Drugs & Pharmaceuticals ltd
BSE: WELCURE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Welcure Drugs & Pharmaceuticals ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Welcure Drugs and Pharmaceuticals Limited is an Indian pharmaceutical company that historically manufactured formulations such as tablets, capsules, and syrups. The company is currently undergoing a period of transition under new management following a change in ownership.
Business Model
The company historically generated revenue through the manufacturing and marketing of pharmaceutical products. Currently, business operations are limited as the entity undergoes a strategic restructuring under new promoters.
Management Commentary
Management is currently focused on navigating a transition phase following a change in ownership via an open offer process. The company is working to redefine its corporate trajectory after a period of significant financial stress.
Growth Outlook
The near-term outlook is defined by the strategic transition initiated by new promoters. Future growth remains contingent on the successful revival of business operations and the implementation of a new corporate strategy.
Key Risks
- Operational Stagnation. The company faces significant risks related to its limited active business operations and the potential inability to restart manufacturing activities.
- Liquidity Risk. Low trading liquidity and minimal market presence may hinder the company's ability to raise capital or maintain its listing status.
- Regulatory Compliance. As a pharmaceutical entity, the company must navigate stringent regulatory requirements and quality standards to resume commercial production.
- Execution Risk. There is uncertainty regarding the new management's ability to successfully turnaround the company's financial position and operational health.
Start your research today
Unlock AI insights, financials, peers and live data on Welcure Drugs & Pharmaceuticals ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹366 Cr
TTM · standalone
NET PROFIT
₹83 Cr
TTM · standalone
EPS
₹3.36
TTM · standalone
RETURN ON EQUITY
81.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
32.6%
TTM · standalone
P/E
0.1x
Q4 FY26 · standalone
EV/EBITDA
0.3x
Q4 FY26 · standalone
NET PROFIT MARGIN
13.0%
Q2 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Welcure Drugs & Pharmaceuticals ltdWELCURE | ₹27 Cr | 0.06 | 0.28 | 569.5% | 25.7% | 81.8% | 32.6% | -96.4% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Welcure Drugs & Pharmaceuticals ltd
BSE: WELCURE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Welcure Drugs & Pharmaceuticals ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Welcure Drugs and Pharmaceuticals Limited is an Indian pharmaceutical company that historically manufactured formulations such as tablets, capsules, and syrups. The company is currently undergoing a period of transition under new management following a change in ownership.
Business Model
The company historically generated revenue through the manufacturing and marketing of pharmaceutical products. Currently, business operations are limited as the entity undergoes a strategic restructuring under new promoters.
Management Commentary
Management is currently focused on navigating a transition phase following a change in ownership via an open offer process. The company is working to redefine its corporate trajectory after a period of significant financial stress.
Growth Outlook
The near-term outlook is defined by the strategic transition initiated by new promoters. Future growth remains contingent on the successful revival of business operations and the implementation of a new corporate strategy.
Key Risks
- Operational Stagnation. The company faces significant risks related to its limited active business operations and the potential inability to restart manufacturing activities.
- Liquidity Risk. Low trading liquidity and minimal market presence may hinder the company's ability to raise capital or maintain its listing status.
- Regulatory Compliance. As a pharmaceutical entity, the company must navigate stringent regulatory requirements and quality standards to resume commercial production.
- Execution Risk. There is uncertainty regarding the new management's ability to successfully turnaround the company's financial position and operational health.
Start your research today
Unlock AI insights, financials, peers and live data on Welcure Drugs & Pharmaceuticals ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹366 Cr
TTM · standalone
NET PROFIT
₹83 Cr
TTM · standalone
EPS
₹3.36
TTM · standalone
RETURN ON EQUITY
81.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
32.6%
TTM · standalone
P/E
0.1x
Q4 FY26 · standalone
EV/EBITDA
0.3x
Q4 FY26 · standalone
NET PROFIT MARGIN
13.0%
Q2 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26